Boris L. Zaïtra

Homburger advised Noema Pharma, a clinical-stage biotech company, on its successful closing of a Series B extension financing round with an investment from EQT Life Sciences, and with continued support from Jeito and Forbion, all advised by BGPartner | Attorneys-at-law. This brings the total capital raised in the round to CHF 130 million. With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, JEITO Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, The Invus Group, and UPMC Enterprises. Homburger advised Noema Pharma as transaction counsel in this Series B extension financing round. The Homburger team comprised partner Andreas Müller, associate Thierry Burckhardt, associate Thomas Romelli, and junior associate Rebecca Sigrist (all corporate/M&A; healthcare/life sciences), partner Luca Dal Molin (IP/IT; healthcare/life sciences) as well as partner Stefan Oesterhelt and associate Laetitia Fracheboud (tax). BGPartner advised EQT, Forbion and Jeito on all Swiss legal matters and the negotiations of this Series B extension and the initial Series B round. The team consisted of Oliver Gnehm (partner-pictured), Victoria Marty (senior associate) and Tessa Douma (associate). Pictured from left to right: Andreas Müller, Luca Dal Molin, Stefan Oesterhelt Read the full article >> https://lnkd.in/d8t6v59B #Legalcommunitych #legaladvisor #financing

30

Our portfolio company, Memo Therapeutics AG announced today it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million. New investors Ysios Capital and Kurma Partners participated in the extension round, joining existing Series C round investors including Verve Ventures, Pureos Bioventures, Swisscanto, Vesalius Biocapital, Adjuvant Capital, Schroders Capital, GF Group, Fresenius Medical Care Ventures and redalpine. The new funding will be used to bolster the clinical advancement of MTx’s lead asset, AntiBKV, expanding the Phase II trial with a dose evaluation extension to be the largest BK viremia therapeutic study ever conducted in kidney transplant recipients. Initial data from the Phase II trial is expected in the first half of 2025. The funding will further support the development of MTx’s pipeline by leveraging its B-cell screening platform to select best-in-class humanized antibodies in other viral infections and oncology. Read the full press release: https://lnkd.in/eireTwgu #health #antibkv #biotech #antibodydiscovery #infectiousdiseases #drugdiscovery #innovation #venturecapital #fundingnews

32

1 Kommentar

BGPartner advises OrbiMed, Novo Holdings and Catalio Capital on $181.4 mio Series D financing of Alentis Therapeutics AG Swiss biotech company Alentis Therapeutics successfully closed a $181.4 mio oversubscribed Series D financing round, supported by a syndicate of top-tier biotech investors. The funding round was led by OrbiMed with co-leads Novo Holdings and JEITO Capital. New investors Frazier Healthcare Partners, Longitude Capital, Catalio Capital Management, Piper Heartland Healthcare Capital and Avego Bioscience Capital in the round. Significant backing was also received from existing investor RA Capital Management, along with support from Morningside Venture Investments, BB Pureos, Bpifrance through its InnoBio 2 fund. The financing will support Alentis Therapeutics AG to develop a deep pipeline of CLDN1 targeted medicines for solid tumors. BGPartner | Attorneys-at-law advised lead investors OrbiMed and Novo Holdings as well as the investor Catalio Capital on all Swiss legal matters and the negotiations of this Series D financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate). More information about our legal and negotiation expertise can be found here: https://lnkd.in/eFQjD5fw. #Financing #swiss #Biotech #law #negotiation #bgpartner

26

Thanks Trending Topics! Georg Haas and I had a super interesting chat about the relevance and importance of innovation in the healthcare ecosystem. Join us as we discuss our recent investment in Rivia and how Erik Scalfaro and his team are disrupting clinical trials from scratch! 🚀 🏥

23

6 Kommentare

This week, BILANZ Wirtschaftsmagazin published its annual ranking of the “richest 100 under 40”, and I am one of them. Thank you very much! Yes, I am not yet 40 years old and yes, I have managed to raise 12.2 million Swiss francs in venture capital so far. However, I must clarify: These millions are not in my personal bank account. Even though this money is not mine, I feel honored because it gives me the opportunity to bring our vision into focus and raise awareness for women’s health. Women’s health has been neglected for years and is now becoming an important societal issue. Yet, it is still inadequately funded and researched. I am proud to be part of this growing industry with Pregnolia and to be able to drive it forward. For many years now, I have been passionate about the topic of Women's Health, especially in pregnancy care. Preterm birth is one of the biggest challenges in modern obstetrics. Since 2017, Pregnolia AG has been actively striving to improve preterm birth diagnostics and working every day to bring our solution into daily clinical practice. Our goal is to help millions of mothers and their babies around the world. We are always looking for investors who share our vision and want to support us on our journey. So, let’s join forces to raise awareness for women's health and especially preterm birth, and work towards a world where every pregnancy goes to full term. If you would like to learn more about Pregnolia and our ongoing financing round, contact me! #financing #pretermbirth

351

41 Kommentare

Austria: Life Science Tools M&A - European Healthcare Investor Association (E.H.I.A.) Investor Member Novo Holdings has acquired a 60% stake in Single Use Support. The two founder shareholders will retain 10% each and Danaher Corporation 20%. Value was not disclosed, but a spokesperson indicated it was a "high triple-digit million euros" amount. Founded in 2017 in Kufstein, Austria by Johannes Kirchmair 👋 and Thomas Wurm, Single Use Support employs 200 people and is transforming the production process for advanced pharmaceutical modalities with its equipment and consumables used in the bioprocessing value chain. With a focus on solutions for biological drug substances, cell and gene therapies, and mRNA vaccines, the company’s customers include leading pharma companies, biotech companies and CDMOs. William Blair were financial and Kromann Reumert, DORDA Rechtsanwälte GmbH, Linklaters and Wilson Sonsini Goodrich & Rosati legal advisors to Novo. Jefferies were financial and E+H Attorneys-at-Law legal advisors to Single Use Support. #healthcare #lifesceinces Johan Hueffer Real Leclerc John Duncan Park

3

Sanofi Switzerland's Michael Kubischik on Leadership, AI, and Patient-Centric Growth Michael Kubischik shares his career journey and Sanofi’s strategic focus in Switzerland. He highlights Sanofi’s dedication to become the world´s leading immunology company, supported by initiatives like AI integration and efficient regulatory processes to improve patient access, as well as the benefits of working for a company with such a deeply-embedded collaborative culture. Read the full interview at https://lnkd.in/dC8JmTqW

11

1 Kommentar

Switzerland – Ideal place for business creation: The country is located in the centre of Europe, less than 2 hours flight time to most European capitals, ranks #1 on the global innovation index for more than 10 consecutive years. It’s multilingual, politically stable, has a large workforce of highly trained people, top notch universities and research institutes, breath-taking natural beauty and a highly diverse and international cultural scene. In addition, it is well suited for company creation and setting up corporate headquarters for large- and small companies. Mayr BioMedTech Consulting (https://lnkd.in/eVVY5C_h) is based in Basel/Switzerland, Europe's hub for Pharma/Biotech/Medtech. Key facts about this country are: - Flexible Labor Laws - Highly Qualified Personnel  - Attractive Tax Environment  - Excellent Infrastructure  - Political Stability  - Proximity to Universities and Research Centers  - High Quality of Life  - International Business Environment  - Cultural Diversity https://lnkd.in/eZrT4Y6U

72

1 Kommentar

YPOG advised lead investor Vesalius Biocapital IV on the Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund, and HTGF | High-Tech Gründerfonds also participated in the investment.   The new funding will support the Phases Ib/ IIa clinical trial focused on improving liver healing and preventing liver failure.   Congratulations to our client Vesalius and all parties involved!   The YPOG team was led by Martin Schaper and included Dr. Lutz Schreiber, Benjamin Müller, Matthias Treude as well as Cyra Dittberner.   ➡ Link to the press release in the comments below.   #YPOG #PartnersOfGamechangers #VentureCapital #Growth #Funds #Transactions

34

2 Kommentare

MedTech and Robotics in Bern !

45

Neo Medical, a Swiss technology company specializing in spine surgery, has announced the successful completion of a strategic equity investment, including the conversion of existing shareholder loans. The financing round was led by Gyrus Capital, advised by Lenz & Staehelin, a private equity firm based in Geneva. Including the participation of existing investors, among which founders Vincent Lefauconnier and Jonas Larsson, this landmark round is one of the most significant in the spine industry in the last decade. With this financing round, Neo has secured an additional equity investment of up to $68 million (CHF 58 million) to accelerate its global growth. Lenz & Staehelin’s team comprised partner Andreas Rötheli (pictured) Federico Trabaldo Togna , E. Ipek Yüce , David Di Rosa, Noé Luisoni, Céline Perone, Victor Sellier (all corporate / M&A), Floran Ponce and Maximilien De Ridder (both tax), Sevan Antreasyan and Anne-Laure Laplace (both IP and regulatory) Read the full article >> https://lnkd.in/dge-Kypf #Legalcommunitych #legaladvisor #investment

36

📍Why does the Basel Area region stand out as Switzerland's densest innovation ecosystem? We believe that innovation is not a solo effort — it thrives on cooperation. With our sites at the Main Campus, Novartis Campus and Jura, the Switzerland Innovation Park Basel Area is a hub where the brightest minds meet, brainstorm and collaborate - surrounded by 700+ life science companies and institutes. Read more about what innovation means to us and discover our virtual Innovation Map tool showcasing our vibrant ecosystem right here: https://lnkd.in/euPBbgrU 🤝Experience the spirit of innovation and collaboration 🔍Explore innovative companies and startups in the Basel Area 🔑Learn why collaboration is key to innovation 🌍Discover the unique features of the Basel Area ecosystem Basel Area Business & Innovation iart - studio for media architectures #Innovation #Collaboration #WhyBaselArea #Startups #LifeScience

43

Marco Toni, Nicolas Wehrli, Gilles Pitschen and Pascal Hammerer have contributed to the Swiss chapter of the 2024 Healthcare M&A Chambers Global Practice Guide.   The guide provides the latest legal information on market trends, establishing healthcare start-ups, including early-stage financing and venture capital, IPOs and private sales, spin-offs, acquisition of listed companies, including stakebuilding, documentation, squeeze-out mechanisms, certain funds requirements and deal protection measures, regulatory requirements, including antitrust, foreign investment review and data privacy concerns, disclosure obligations, and duties of directors.   Click here to read the full chapter: https://lawand.tax/3RAAfah   #healthcare #lifesciences #Switzerland #lawandtax

43

Private equity giant CVC has made a €1.2 billion offer for CompuGroup Medical that will remove the German e-health company from Germany's bourse. https://lnkd.in/e-UQhvsr

1

https://lnkd.in/dgU8x9fm SBB CFF FFS client services decline to a French client services level. my teenage child's yearly train ticket "GA" blocked, as the photo is showing her 5 years younger. SBB CFF FFS client centers in Zurich and Oerlikon, online forms and client interfaces are INCAPABLE TO UPDATE A PHOTO of a yearly train abonnement. Since more than a year I try regularly to do a photo update with client services. Each time SBB CFF FFS personnel tells me that I did everything correctly, now I have to wait a bit "it takes a few weeks but the updated photo will be treated". This way a year has passed, the photo is still the same, and finally her train abonnement is blocked. Yesterday an @sbbcffffs conductor told me to call Alliance SwissPass. Their answer is: "we have no access to @sbbcffffs client data. Please talk to @sbbcffffs hotline. Hotline: "there are 10 persons before you. please call later again." Now my teenager risks every day to get a fine for travelling with a blocked ticket. Anyone knows a contact at SBB CFF FFS that may answer to client requests? #clientservices #publictransport #productionprocesses #processengineering #teenagers #mobility

2

Where have the successful biotech companies gone? Interesting article in the Finanz und Wirtschaft News. In a nutshell: Following the coronavirus vaccine boom in recent years, biotech shares have experienced a boom this year 🚀 However, many listed biotech companies are still trading below their issue price. So no hope? 🌦️ I don't think so. Setbacks and uncertainty are part of everyday life in this sector. Many roads lead to Rome.   Clinical results are not the only decisive factor for success, but also and even more an experienced team, a functioning Board of Directors, clear go-to-market strategy, perseverance and investor support.   The interest rate policy in 2025 should again support investments in research & development. Let's hope for many positive press releases in the new year!  🌞 https://lnkd.in/d2BKUibF

11